. 2016 Jan 25;11(1):e0147821. doi: 10.1371/journal.pone.0147821

Table 4. Calibrated monthly virologic suppression and virologic failure probabilities.

Therapy Line	ART Regimen	Monthly Probability of Discontinuation		Source
Therapy Line	ART Regimen	First year	Subsequent Years	Source
1^st Line	EFV/TDF/FTC	1.09%	0.50%	GS-236-102 [18–20]
STR	RPV/TDF/FTC	0.91%	0.61%	STAR Study [21, 22]
	EVG/COBI/TDF/FTC	0.84%	0.56%	GS-236-102 [18–20]
1^st Line	gEFV+TDF+g3TC	1.36%	0.46%	Study 903 [23, 24]
gMTR	RPV+TDF+g3TC	1.14%	0.56%	Assumption^a
	EVG+COBI+TDF+g3TC	1.05%	0.52%	Assumption^a
2^nd Line	ATV/r + TDF/FTC	0.71%	0.79%	BMS Study 045 [25, 26]
3^rd Line	DRV/r + TDF/FTC	1.04%	1.28%	POWER 1–2 [27–31]
4^th Line	DTG + TDF/FTC	0.94%	0.10%	SAILING [32, 33]
5^th Line	DRV/r + DTG + TDF/FTC	1.15%	1.22%	VIKING [34]
6^th Line	ENF + OBR	1.83%	2.13%	TORO 1–2 [35, 36]

/r, ritonavir boosted; ATV, atazanavir; COBI, cobicistat; DRV, darunavir; DTG, dolutegravir; EFV, efavirenz; ENF, enfuvirtide; EVG, elvitegravir; FTC, emtricitabine; g3TC, generic lamivudine; gEFV, generic efavirenz; OBR, optimized background regimen; RPV, rilpivirine; TDF, tenofovir.

^aSimilar procedure as for the assumptions in Table 3.